Kevin Sweeney is a strategic partner to many emerging and established companies, assisting in the development and implementation of their business, financial, and legal goals. His particular emphasis is serving as an advisor to the top management of life sciences companies.
His understanding and appreciation of the scientific and humanitarian mission of these entities was fostered by early work for entities such as Marion Laboratories, BioTechnica International, and AVAX Technologies. His passion continues to be cultivated by working with numerous entities that advance human health, animal health, plant science, "green" and industrial technologies, and biosafety and homeland security sciences, as well as computer and software technologies.
One of most exciting endeavors of Kevin’s career was the opportunity to work with Nobel Laureate Dr. Sydney Brenner to co-found the Molecular Sciences Institute in Berkeley, Calif., as one of the leading multidisciplinary basic scientific institutes focused on predictive biology.
As Chair of the Polsinelli Multidisciplinary Life Sciences Practice Group and a senior member of its Corporate Finance Practice Group, Kevin has more than 25 years of experience handling:
- Mergers and acquisitions
- Public and private securities offerings
- Venture capital financing
- Technology transfer
- Other complex financial and strategic transactions
Kevin uses his broad contacts in the national scientific, academic, business, and financial communities to assist companies, universities, and other scientific organizations. In leading complex securities, venture capital, private equity, and merger and acquisition transactions, Kevin coordinates and integrates the efforts of investment and commercial bankers, accountants, and other experts.
With extensive experience in the boardroom, Kevin served as a key advisor to the board of directors of numerous public and private companies, advising them on corporate, finance, fiduciary, and SEC issues. He represented independent committees in related-party transactions and investigations of alleged management improprieties, and he advises audit committees, compensation committees, finance committees, and boards of directors.